Last reviewed · How we verify
Long-Term Safety Follow-up
At a glance
| Generic name | Long-Term Safety Follow-up |
|---|---|
| Sponsor | Sollis Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder (PHASE2)
- Pain Management Teams Using Whole Health to Optimize Function and Safety in Veterans: The TEAMWORK Trial (NA)
- Evaluation of a Telehealth Case Management Intervention to Prevent Suicide Among Soldiers Discharged From Psychiatric Hospitalization (NA)
- Long Term Follow-up for RGX-202
- Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis (PHASE2, PHASE3)
- A Study of Soticlestat in Adults and Children With Rare Epilepsies (PHASE2)
- Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (PHASE3)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Long-Term Safety Follow-up CI brief — competitive landscape report
- Long-Term Safety Follow-up updates RSS · CI watch RSS
- Sollis Therapeutics, Inc. portfolio CI